Neumora Therapeutics, Inc. NMRA
We take great care to ensure that the data presented and summarized in this overview for Neumora Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NMRA
Top Purchases
Top Sells
About NMRA
Insider Transactions at NMRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 18
2024
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
14,049
-41.14%
|
$238,833
$17.03 P/Share
|
|
Oct 18
2024
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
14,049
+18.88%
|
$70,245
$5.66 P/Share
|
|
Oct 17
2024
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
7,739
-27.8%
|
$131,563
$17.01 P/Share
|
|
Oct 17
2024
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
7,739
+9.14%
|
$46,434
$6.54 P/Share
|
|
Oct 10
2024
|
Robert A. Lenz Head of R&D |
SELL
Open market or private sale
|
Direct |
8,260
-2.56%
|
$123,900
$15.09 P/Share
|
|
Oct 09
2024
|
Robert A. Lenz Head of R&D |
SELL
Open market or private sale
|
Direct |
5,563
-1.69%
|
$83,445
$15.01 P/Share
|
|
Sep 18
2024
|
Robert A. Lenz Head of R&D |
SELL
Open market or private sale
|
Direct |
10,676
-3.15%
|
$128,112
$12.09 P/Share
|
|
Sep 17
2024
|
Robert A. Lenz Head of R&D |
SELL
Open market or private sale
|
Direct |
30,788
-8.32%
|
$338,668
$11.81 P/Share
|
|
Sep 12
2024
|
Robert A. Lenz Head of R&D |
SELL
Open market or private sale
|
Direct |
32,948
-8.18%
|
$362,428
$11.43 P/Share
|
|
Aug 27
2024
|
Joshua Pinto Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
15,693
-10.15%
|
$172,623
$11.39 P/Share
|
|
Aug 26
2024
|
Joshua Pinto Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
31,642
-16.98%
|
$348,062
$11.78 P/Share
|
|
Aug 23
2024
|
Joshua Pinto Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
24,169
-11.48%
|
$265,859
$11.59 P/Share
|
|
Aug 22
2024
|
Joshua Pinto Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
28,496
-11.92%
|
$313,456
$11.63 P/Share
|
|
Jun 13
2024
|
Alaa Halawa |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+50.0%
|
-
|
|
Jun 13
2024
|
David Piacquad |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+50.0%
|
-
|
|
Jun 13
2024
|
Maykin Ho |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+50.0%
|
-
|
|
Jun 13
2024
|
Kristina Burow |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+29.64%
|
-
|
|
Jun 13
2024
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
20,100
+50.0%
|
-
|
|
Apr 22
2024
|
Daljit Singh Aurora Chief Strategy Officer |
SELL
Bona fide gift
|
Direct |
114,703
-54.05%
|
-
|
|
Apr 17
2024
|
Joshua Pinto Chief Financial Officer |
SELL
Bona fide gift
|
Indirect |
238,965
-50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
712K
Shares
From
13
Insiders
| Grant, award, or other acquisition | 690K shares |
|---|---|
| Exercise of conversion of derivative security | 21.8K shares |
Sell / Disposition
564K
Shares
From
5
Insiders
| Open market or private sale | 210K shares |
|---|---|
| Bona fide gift | 354K shares |